Lee’s Pharmaceutical

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that it has entered into an exclusive licensing...

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Fineline Cube Jul 20, 2026

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced an exclusive license agreement with Ashlins Ocular Pharmaceuticals,...

Company Drug

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Fineline Cube Mar 26, 2026

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) announced National Medical Products Administration (NMPA) marketing approval for...

Company Deals

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Fineline Cube Dec 10, 2025

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that its wholly‑owned subsidiary Nova Pneuma Inc. (NPI)...

Company Drug

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Fineline Cube Aug 1, 2025

Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced that its in-licensed programmed-death ligand 1 (PD-L1) monoclonal...

Company Deals

Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions

Fineline Cube Jul 31, 2025

China-based Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced on July 28, 2025, that it has...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023

Fineline Cube Mar 28, 2025

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4...

Company Drug

Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2025

China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Drug

Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD

Fineline Cube Jan 2, 2025

China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Drug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Fineline Cube Dec 10, 2024

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Drug

Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment

Fineline Cube Nov 5, 2024

US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT) has announced the receipt of a patent...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study

Fineline Cube Oct 24, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Company Drug

Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan

Fineline Cube Sep 20, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Drug

Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial

Fineline Cube Aug 12, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a prominent Chinese pharmaceutical company, through its subsidiary Zhaoke...

Company Drug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Fineline Cube Aug 2, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading biopharmaceutical company based in China, has announced...

Company Deals

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Fineline Cube Jun 5, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, has announced that its subsidiary,...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs

Fineline Cube Mar 27, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...

Company Deals

Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment

Fineline Cube Mar 7, 2024

Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary...

Company Deals

Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF

Fineline Cube Jan 29, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a China-based pharmaceutical company, through its subsidiary Zhaoke Ophthalmology...

Company Deals

Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China

Fineline Cube Jan 19, 2024

Lee’s Pharmaceutical Ltd (HKG: 0950) has entered into a licensing agreement with US-based Windtree Therapeutics...

Lee’s Pharmaceutical

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Lee’s Pharmaceutical Enters Exclusive Global Licensing Agreement with Ashlins Ocular for Interferon Alpha-2b Outside Greater China

Lee’s Pharma Wins NMPA Approval for Intrarosa – Estrogen-Free DHEA Pessary Targets Postmenopausal Vulvovaginal Atrophy

Lee’s Pharm Staccato-OBT Acquisition Bolsters UCB Partnership

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Lee’s Pharma Partners with Shaohe Biotech to Translate Probiotics into Public Health Solutions

Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023

Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA

Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study

Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan

Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs

Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment

Zhaoke Ophthalmology Strikes Distribution Deal with South Korea’s Kwangdong Pharmaceutical for Brimochol PF

Lee’s Pharmaceutical to Develop Windtree’s Cardiovascular Drugs in Greater China

You Missed

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories